Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Critical Care Medicine|December 17, 2002
Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock modelEduardo R C Schiffer, Guido Reber, Philippe De Moerloose, et al.Thrombosis and Haemostasis|November 5, 2005
Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assaysGuido Reber, Angela Tincani, Marielle Sanmarco, et al.Thrombosis and Haemostasis|September 4, 2008
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolismPhilippe de Moerloose, Gualtiero Palareti, Carlos Aguilar, et al.Annals of the New York Academy of Sciences|September 6, 2007
An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay resultsAnna Cavazzana, Amelia Ruffatti, Marta Tonello, et al.Modern Rheumatology|November 21, 2013
Felty's syndrome and hypofibrinogenemia: an unusual target for anti-cyclic citrullinated peptide antibodies?Ilias Lazarou, Nicolas Petitpierre, Isabelle Auger, et al.Thrombosis Research|October 28, 2004
Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodiesAngela Tincani, Flavio Allegri, Genesio Balestrieri, et al.Intensive Care Medicine|July 14, 2006
Point of care management of heparin administration after heart surgery: A randomized, controlled trialPaolo G Merlani, Catherine Chenaud, Silvia Cottini, et al.Thrombosis and Haemostasis|November 13, 2002
NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodiesSylvie Dunoyer-Geindre, Philippe de Moerloose, Béatrix Galve-de Rochemonteix, et al.Journal of Autoimmunity|December 2, 2004
Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular diseaseNicolas Vuilleumier, Guido Reber, Richard James, et al.Revue Medicale Suisse|March 12, 2010
[Evaluating the biological efficacy of clopidogrel: genotype or phenotype?]Pierre Fontana, Robert F Bonvini, Marco Roffi, et al.Pageof 4